In this episode from the series “Key Decisions in HIV Care,” Latesha Elopre, MD, MSPH, and Karine Lacombe, MD, PhD, discuss important considerations for PrEP in cisgender men and transgender women, including:Discussion of the PrEP gap and racial and gender disparities in PrEP access CDC, EACS, and WHO guidance on PrEP eligibility PrEP regimens currently recommended for adults and adolescents including FTC/TDF daily, FTC/TAF daily, and long-acting cabotegravir Data from clinical trials on the efficacy of FTC/TDF daily for men including Partners PrEP, TDF2, iPrEx, iPrEx OLE, and PROUD Data from the ANRS IPERGAY study on the use of FTC/TDF on demand Data from the DISCOVER trial on the use of FTC/TAF for PrEP Data from the HPTN 083 study on the use of long-acting cabotegravir as PrEP for cisgender men Clinical monitoring and considerations during PrEP usePresenters:Latesha Elopre, MDAssociate ProfessorDivision of Infectious DiseasesAssistant Dean of Diversity and InclusionGeneral Medical EducationUniversity of Alabama at BirminghamBirmingham, AlabamaKarine Lacombe, MD, PhDProfessorUMR-S1136Sorbonne UniversityHead, Infectious Diseases DepartmentSt Antoine Hospital, AP-HPParis, FranceContent based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with the slides at:https://bit.ly/3uqPje3Link to full program:https://bit.ly/3q2DlGd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related